Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shares fell 4.3% during mid-day trading on Friday . The stock traded as low as $8.93 and last traded at $9.06. 436,341 shares traded hands during trading, a decline of 83% from the average session volume of 2,550,550 shares. The stock had previously closed at $9.46.
Wall Street Analyst Weigh In
NTLA has been the topic of a number of analyst reports. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Barclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $36.90.
Check Out Our Latest Stock Analysis on NTLA
Intellia Therapeutics Stock Performance
The company has a market cap of $950.37 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. The business's 50 day moving average price is $7.98 and its 200-day moving average price is $10.63.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter last year, the firm posted ($1.12) earnings per share. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Intellia Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after buying an additional 44,022 shares in the last quarter. SG Americas Securities LLC raised its stake in Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after acquiring an additional 20,694 shares in the last quarter. KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after acquiring an additional 2,340 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after acquiring an additional 2,059 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $185,000. 88.77% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
